Biocon shares jump 8% post Q4 results. Is the Street happy? Biocon's shares surged by 8% on Tuesday due to strong Q4 earnings ...
Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to ...
At around 10:42 a.m., Biocon shares were up 1.51 per cent, or Rs 3.6, at Rs 242.05 apiece on BSE. The market capitalisation ...
Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™ (Denosumab biosimilars to Prolia® and Xgeva®) for bone health.
In the last one year, shares of Biocon zoomed up to 17 per cent, while on a year-to-date basis it cracked over 13 per cent.
Bengaluru/Toronto: Biocon is stepping up its global biosimilars play with fresh approvals in Canada, targeting large patient ...
Biocon chairperson Kiran Mazumdar-Shaw unveils corporate commute nudge under Toyota Mobility Foundation and WRI India’s STAMP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results